Skip to content

Released Nov 7, 2024, before the open

10-Q filed Nov 7, 2024, 38 days after period end · 0001764013-24-000184

Q2 2025 · 10-Q
Revenue—
Net Income-$109.12MN/M vs Q2 2024N/M vs Q1 2025
EPS Diluted-$0.74N/M vs Q2 2024N/M vs Q1 2025
Operating Cash Flowderived-$88,647,000N/M
Free Cash Flowderived-$88,843,000N/M

What the release said

The release

Same quarter

MetricQ2 2025Q2 2024Q2 2023Q2 2022
Net Income-$109.12M-$58.66M-$47.93M-$37.70M
EPS Diluted-$0.74-$0.45-$0.41-$0.35

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Immunovant, Inc. · CIK 1764013 · Engraved from SEC EDGAR